Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Atreca Q2 EPS $(0.72), Same YoY

Atreca Q2 EPS $(0.72), Same YoY

Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.72) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

August 8, 2022

1 minute read

Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.72) per share. This is unchanged from the same period last year.

Recap: Becton, Dickinson Q3 Earnings

By Benzinga Insights

August 4, 7:28 AM

Becton, Dickinson (NYSE:BDX) reported its Q3 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

BDX

Iron Mountain Inc Maintained FY23 Revenue $5.5B-$5.6B Vs $5.54B Est, AFFO Per Share $3.91-$4.00

By Benzinga Newsdesk

November 2, 6:49 AM

2023 Guidance(1) ($ in millions, except per share

IRM

Materialise Q1 Revenue Soars 24.4% YoY, Beating Estimates With Strong Segment Growth

By Anusuya Lahiri

April 27, 11:44 AM

Materialise NV (NASDAQ: MTLS) reported first-quarter FY23 revenue growth of 24.4% year-on-year to $71.65 million (€65.89 million), beating the

MTLS

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

June 20, 12:29 PM

Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.

JAZZ

Atreca Q2 EPS $(0.72), Same YoY

Related Posts

Recap: Becton, Dickinson Q3 Earnings

Iron Mountain Inc Maintained FY23 Revenue $5.5B-$5.6B Vs $5.54B Est, AFFO Per Share $3.91-$4.00

Materialise Q1 Revenue Soars 24.4% YoY, Beating Estimates With Strong Segment Growth

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?